JPMorgan Chase & Co. Increases Stock Holdings in Neuronetics, Inc. (NASDAQ:STIM)

JPMorgan Chase & Co. boosted its holdings in shares of Neuronetics, Inc. (NASDAQ:STIM) by 10,954.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,939 shares of the company’s stock after buying an additional 54,442 shares during the period. JPMorgan Chase & Co. owned approximately 0.18% of Neuronetics worth $88,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, David J Yvars Group increased its holdings in shares of Neuronetics by 47.1% during the fourth quarter. David J Yvars Group now owns 46,325 shares of the company’s stock valued at $75,000 after acquiring an additional 14,825 shares in the last quarter. 53.59% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group lifted their target price on shares of Neuronetics from $5.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th.

Neuronetics Price Performance

NASDAQ STIM opened at $4.50 on Tuesday. The company has a market cap of $296.17 million, a price-to-earnings ratio of -3.66 and a beta of 1.92. The company has a debt-to-equity ratio of 4.90, a current ratio of 3.16 and a quick ratio of 2.87. The stock’s fifty day moving average price is $4.25 and its 200 day moving average price is $2.75. Neuronetics, Inc. has a 1 year low of $0.52 and a 1 year high of $5.92.

Insider Activity

In other Neuronetics news, CEO Keith J. Sullivan sold 40,992 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $3.28, for a total transaction of $134,453.76. Following the completion of the transaction, the chief executive officer now directly owns 1,283,362 shares of the company’s stock, valued at approximately $4,209,427.36. This trade represents a 3.10 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Stephen Furlong sold 17,307 shares of Neuronetics stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $4.11, for a total transaction of $71,131.77. Following the sale, the chief financial officer now owns 454,420 shares of the company’s stock, valued at approximately $1,867,666.20. The trade was a 3.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 100,369 shares of company stock valued at $358,929. Company insiders own 8.70% of the company’s stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.